目的 觀察前列地爾治療短暫性腦缺血發(fā)作的臨床療效.方法 選擇2011 年1 月-2014 年5 月在天津市武清區(qū)人民醫(yī)院就診的短暫性腦缺血患者100 例,隨機(jī)分為對照組和治療組,每組各50 例.對照組采用常規(guī)治療,治療組在常規(guī)治療基礎(chǔ)上靜脈滴注前列地爾注射液,2 mL/次加生理鹽水10 mL 直接入小壺靜脈滴注.兩組均連續(xù)治療15 d.觀察兩組的臨床療效,同時(shí)比較治療前后兩組凝血指標(biāo)、血液黏度指數(shù)和血流動(dòng)力學(xué)參數(shù)的變化.結(jié)果 治療后,對照組和治療組的總有效率分別為82.0%、94.0%,兩組總有效率比較差異有統(tǒng)計(jì)學(xué)意義(P< 0.05).治療前后兩組血小板計(jì)數(shù)(PLT)、凝血酶原時(shí)間(PT)、活化部分凝血酶原時(shí)間(APTT)差異均無統(tǒng)計(jì)學(xué)意義.治療后,兩組全血黏度、血漿黏度、纖維蛋白原、腦血管阻力(R)均較治療前顯著降低,兩組最大血流速度(V_max)、最小血流速度(V_min)、平均血流速度(V_mean)、平均血流量(Q_mean)均較治療前顯著升高,同組治療前后差異有統(tǒng)計(jì)學(xué)意義(P< 0.05),且治療組這些觀察指標(biāo)的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P< 0.05).結(jié)論 前列地爾治療短暫性腦缺血發(fā)作具有較好的臨床療效,無明顯副作用,具有高效、安全等優(yōu)點(diǎn),值得臨床推廣應(yīng)用.

Objective To observe the effect of alprostadil in treatment of transient ischemic attack. Methods Patients (100 cases) with transient ischemic attack in the People's Hospital of Wuqing District in Tianjin from January 2011 to May 2014 were randomly divided into control and treatment groups, and each group had 50 cases. The patients in the control group were given conventional treatment. The patients in the treatment group were iv administered with Alprostadil Injection, 2 mL/time added in 10 mL physiological saline directly into a small pot of iv drip. Two groups were treated for 15 d. After treatment, the efficacy was evaluated, and the changes of blood coagulation indexes, viscosity indexes, and cerebrovascular hemodynamic parameters before and after treatment in two groups were compared. Results The efficacies in the control and treatment groups were 82.0% and 94.0%, respectively, and there were differences between two groups (P < 0.05). After treatment, there was no statistically significant difference on PLT, PT, and APTT in the two groups. After treatment, the whole blood viscosity, plasma viscosity, fibrinogen, and cerebral vascular resistance (R) in two groups were significantly reduced, and the V_max, V_min, V_mean, and Q_mean in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). These indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Alprostadil has good clinical efficacy in treatment of transient ischemic attack with no obvious adverse reaction, and has the advantages of high efficiency and safety, which is worthy of clinical popularization and application.